Navigation Links
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
Date:11/23/2009

SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228)

Dr. Steven Reed, IDC's founder and Chief Executive Officer commented, "I am delighted to welcome Dr. Bruce Carter as a new member of IDC's management team and Board of Directors. His appointment and his broad biotech experience signifies our commitment to building a strong company that delivers on its scientific objectives. He is a great addition to IDC."

"With Dr. Steven Reed's expertise on vaccine adjuvants and Dr. David Baltimore's and Dr. Thomas Dubensky's expertise on the lentivirus-based vectors to introduce antigens to dendritic cells, IDC is poised to develop new improved vaccines to a world that desperately needs them," said Dr. Carter.

Dr. Carter possesses a unique combination of strong leadership skills and technical expertise in progressing healthcare products from the bench to the clinic, and ultimately to the people who need them.

Dr. Carter currently serves on the Board of ZymoGenetics, Dr. Reddy's Laboratories, the Hyderabad, India based generic drug maker, QLT, Inc. Vancouver, Canada and the nonprofit Global Alliance TB Drug Development Board, New York, NY. He joins IDC after a long career in the biotechnology and pharmaceutical arena.

Dr. Carter began his career in drug discovery at G. D. Searle. In 1986, he was appointed as V.P. and Head of Research & Development at ZymoGenetics. In 1994 he became a Corporate Executive V.P. at Novo Nordisk, as well as Chief Scientific Officer. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk and he became the CEO transforming the company from the research arm of a European company to a company that developed and commercialized Recothrom®.

IDC - Innovative Science

IDC's goal is to develop and commercialize new safe and effective vaccine products to prevent or target infectious and malignant diseases. IDC utilizes proprietary Toll-like receptor-4 agonist adjuvant and lentivirus-based vector platforms, which both target dendritic cells and are used to deliver antigens together with desired immunostimulatory signals.

For more information, go to www.immunedesign.com.


Contact:

Cassie Ostrander 206-826-7901 or
cassie.ostrander@immunedesign.com

SOURCE Immune Design Corp.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
2. RNL BIO Rescues a College Student from Autoimmune Hearing Loss
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
5. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
6. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
7. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
8. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
9. Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**
10. AutoImmune Inc. Reports 2009 Second Quarter Financial Results
11. Transposagen Creates a Rat Model of the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies to join the University ... a spin out from The Wistar Institute, and Sanguis, launched by a trio of ... Street. , Vironika is developing a treatment for a chronic viral infection and ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
(Date:1/20/2017)... Jan. 20, 2017 Ginkgo Bioworks, the ... a pioneer in the synthesis and assembly of ... in assembling pathway-length synthetic DNA into Ginkgo,s automated ... in the construction of new organism designs for ... "Gen9 was founded to significantly increase the ...
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
Breaking Biology Technology:
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):